Trend Analysis of Anti-Viral Drugs Approved by USFDA during 2019-2023

Introduction

The discovery of new drugs is crucial for pharmaceutical research, development and patient care. One way to achieve this goal is by repurposing existing pharmaceuticals, which can provide valuable insights into their development trends and aid in the systematic creation of new drugs. The FDA’s CDER (Center for Drug Evaluation and Research) compiles an annual summary of novel pharmaceuticals, some of which are truly unique and contribute to the advancement of therapeutic therapy. We examined the FDA’s trends in medicine approval over the past 50 years. We compiled data on the number of new pharmaceuticals developed between 2019 and 2023, including the number of anti-viral drugs. I presented the graphs and analyzed the reasons for medication rejections before concluding.

Aim

This project aims to study and analyze the list of Anti-viral drugs Approved by USFDA From 2019-2023.

Background

The United States Food and Drug Administration (USFDA) has developed and approved antiviral medications at a significantly faster pace in recent years in response to the ongoing threat that various viral diseases offer to the world. Effective therapies against both recognized and developing viral infections are desperately needed and the pharmaceutical sector has shown a remarkable commitment to meeting this need between 2019 and 2023.

Materials and Methods

The study gathered data from the FDA’s online database on innovative medicine approvals between 2019 and 2023.

Results

Out of the 216 new pharmaceuticals approved in the last five years, just 24 are biologics. According to these results, fewer Investigational New Drug Applications (INDAs) are being filed under the antiviral and antibiotic categories.

Conclusion

Our findings show that upholding safety and efficacy requirements is essential to the development of new pharmaceuticals. Our analysis also clarifies the causes of drug rejections, highlighting the need to follow FDA guidelines to avert regulatory action.